Articles by Timothy M. Pawlik, MD
ACR Appropriateness Criteria® Borderline and Unresectable Pancreas Cancer
ByWilliam Small, Jr, MD,John P. Hayes, MD,W. Warren Suh, MD, MPH,May Abdel-Wahab, MD, PhD,Ross A. Abrams, MD,Nilofer Azad, MD,Prajnan Das, MD, MS, MPH,Jadranka Dragovic, MD,Karyn A. Goodman, MD,Salma K. Jabbour, MD,William E. Jones III, MD,Andre A. Konski, MD, MBA, MA,Albert C. Koong, MD, PhD,Rachit Kumar, MD,Percy Lee, MD,Timothy M. Pawlik, MD,Joseph M. Herman, MD, MSc These guidelines review the use of radiation, chemotherapy, and surgery in borderline and unresectable pancreas cancer. Radiation technique, dose, and targets were evaluated, as was the recommended chemotherapy, administered either alone or concurrently with radiation. This report will aid clinicians in determining guidelines for the optimal treatment of borderline and unresectable pancreatic cancer.
ACR Appropriateness Criteria® Resectable Stomach Cancer
ByParima Daroui, MD, PhD,Salma K. Jabbour, MD,Joseph M. Herman, MD, MSc,May Abdel-Wahab, MD, PhD,Nilofer Azad, MD,A. William Blackstock, MD,Prajnan Das, MD,Karyn A. Goodman, MD,Theodore S. Hong, MD,William E. Jones III, MD,Harmeet Kaur, MD,Andre A. Konski, MD, MBA, MA,Albert C. Koong, MD, PhD,Rachit Kumar, MD,Timothy M. Pawlik, MD,William Small, Jr, MD,Charles R. Thomas, Jr, MD,W. Warren Suh, MD, MPH For resectable gastric cancer, perioperative chemotherapy or adjuvant chemoradiation with chemotherapy are standards of care. The decision making for adjuvant therapeutic management can depend on the stage of the cancer, lymph node positivity, and extent of surgical resection.
Tumors of neuroendocrine origin arising from the pancreas, luminal gastrointestinal tract, and other tissues differ greatly in their malignant potential.
